Targeting the transcription factor Myb by small-molecule inhibitors

Research output: Contribution to journalArticlepeer-review

Standard

Targeting the transcription factor Myb by small-molecule inhibitors. / Uttarkar, Sagar; Frampton, Jonathan; Klempnauer, Karl-heinz.

In: Experimental Hematology, Vol. 47, 01.03.2017, p. 31-35.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Uttarkar, Sagar ; Frampton, Jonathan ; Klempnauer, Karl-heinz. / Targeting the transcription factor Myb by small-molecule inhibitors. In: Experimental Hematology. 2017 ; Vol. 47. pp. 31-35.

Bibtex

@article{3e2458c616524310926ffa3c196eef35,
title = "Targeting the transcription factor Myb by small-molecule inhibitors",
abstract = "The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.",
author = "Sagar Uttarkar and Jonathan Frampton and Karl-heinz Klempnauer",
year = "2017",
month = mar,
day = "1",
doi = "10.1016/j.exphem.2016.12.003",
language = "English",
volume = "47",
pages = "31--35",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Targeting the transcription factor Myb by small-molecule inhibitors

AU - Uttarkar, Sagar

AU - Frampton, Jonathan

AU - Klempnauer, Karl-heinz

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.

AB - The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.

U2 - 10.1016/j.exphem.2016.12.003

DO - 10.1016/j.exphem.2016.12.003

M3 - Article

VL - 47

SP - 31

EP - 35

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

ER -